Skip to main content

Small Renal Mass Cryoablation: Trifecta Outcomes of a Single-Institution Experience with a 20-Year Follow-Up.

Publication ,  Journal Article
Mottaghi, M; Ghoreifi, A; Deivasigamani, S; Balaji, S; Adams, ES; Tsivian, M; Kim, CY; Polascik, TJ
Published in: Cancers (Basel)
September 10, 2025

BACKGROUND/OBJECTIVES: Cryoablation is a minimally invasive treatment option for patients with a small renal mass (SRM). We aimed to present the long-term functional and oncologic outcomes of cryoablation for SRMs. METHODS: We retrospectively reviewed patients treated with percutaneous or laparoscopic cryoablation for an SRM (≤4 cm in diameter) at our tertiary hospital between October 2001 and December 2011. Primary outcomes included technical failure (persistent CT enhancement post-ablation) and progression (local recurrence or metastasis). Trifecta is defined as the absence of severe complications (Clavien-Dindo > 2), no oncological progression, and ≤10% decline in eGFR. RESULTS: A total of 129 patients with a median age of 67 (IQR 58-74) years were analyzed. The median (IQR) clinical and radiologic follow-ups across all patients were 136 (54-180) and 74 (23-147) months, respectively, with a median (IQR) tumor volume of 3.3 (1.6-6.6) cm3. Among those with available biopsy data (n = 86), 62 (72%) were diagnosed with Renal Cell Carcinoma (RCC), and 24 (28%) exhibited benign pathologies, including angiomyolipoma, oncocytic neoplasm, and non-diagnostic pathology. Of all patients, six experienced high-grade complications. Among non-solitary kidney patients with available creatinine values between 13 and 36 months post-treatment, 64% had ≤10% eGFR decline compared to baseline. Notably, 58% (26/48) of patients with RCC (non-solitary kidney) achieved our trifecta definition at 36 months. Metastasis-free, cancer-specific, and overall survival at 15-year follow-up were 85%, 96%, and 46%, respectively. Univariable regression identified tumor volume and solitary kidney status at ablation as significant predictors for oncological progression. CONCLUSIONS: Cryoablation for the SRM showed sustained oncological and functional efficacy over long-term follow-up.

Duke Scholars

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

September 10, 2025

Volume

17

Issue

18

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mottaghi, M., Ghoreifi, A., Deivasigamani, S., Balaji, S., Adams, E. S., Tsivian, M., … Polascik, T. J. (2025). Small Renal Mass Cryoablation: Trifecta Outcomes of a Single-Institution Experience with a 20-Year Follow-Up. Cancers (Basel), 17(18). https://doi.org/10.3390/cancers17182960
Mottaghi, Mahdi, Alireza Ghoreifi, Sriram Deivasigamani, Sudharshanan Balaji, Eric S. Adams, Matvey Tsivian, Charles Y. Kim, and Thomas J. Polascik. “Small Renal Mass Cryoablation: Trifecta Outcomes of a Single-Institution Experience with a 20-Year Follow-Up.Cancers (Basel) 17, no. 18 (September 10, 2025). https://doi.org/10.3390/cancers17182960.
Mottaghi M, Ghoreifi A, Deivasigamani S, Balaji S, Adams ES, Tsivian M, et al. Small Renal Mass Cryoablation: Trifecta Outcomes of a Single-Institution Experience with a 20-Year Follow-Up. Cancers (Basel). 2025 Sep 10;17(18).
Mottaghi, Mahdi, et al. “Small Renal Mass Cryoablation: Trifecta Outcomes of a Single-Institution Experience with a 20-Year Follow-Up.Cancers (Basel), vol. 17, no. 18, Sept. 2025. Pubmed, doi:10.3390/cancers17182960.
Mottaghi M, Ghoreifi A, Deivasigamani S, Balaji S, Adams ES, Tsivian M, Kim CY, Polascik TJ. Small Renal Mass Cryoablation: Trifecta Outcomes of a Single-Institution Experience with a 20-Year Follow-Up. Cancers (Basel). 2025 Sep 10;17(18).

Published In

Cancers (Basel)

DOI

ISSN

2072-6694

Publication Date

September 10, 2025

Volume

17

Issue

18

Location

Switzerland

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis